Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
1.–5. rezultāts no 100.
26. lappuse
... Results of tests conducted on the batch by or for the manufacturer and the batch pro- duction record shall accompany the sample . ( iii ) Withhold the batch from dis- tribution until he is notified by the Food and Drug Administration ...
... Results of tests conducted on the batch by or for the manufacturer and the batch pro- duction record shall accompany the sample . ( iii ) Withhold the batch from dis- tribution until he is notified by the Food and Drug Administration ...
74. lappuse
... results of a sponsor's inves- tigation show that an adverse drug ex- perience not initially determined to be reportable under paragraph ( c ) of this section is so reportable , the sponsor shall report such experience in a writ- ten ...
... results of a sponsor's inves- tigation show that an adverse drug ex- perience not initially determined to be reportable under paragraph ( c ) of this section is so reportable , the sponsor shall report such experience in a writ- ten ...
75. lappuse
... results of a sponsor's investiga- tion show that an adverse experience not ini- tially determined to be reportable under paragraph ( c ) of this section is so reportable , the sponsor shall report such experience in a safety report as ...
... results of a sponsor's investiga- tion show that an adverse experience not ini- tially determined to be reportable under paragraph ( c ) of this section is so reportable , the sponsor shall report such experience in a safety report as ...
96. lappuse
... results of his or her research , the physician is obliged to preserve the accuracy of the results . Reports of ex- perimentation not in accordance with the principles laid down in this Declaration should not be accepted for publication ...
... results of his or her research , the physician is obliged to preserve the accuracy of the results . Reports of ex- perimentation not in accordance with the principles laid down in this Declaration should not be accepted for publication ...
105. lappuse
... results of in vitro preclinical stud- ies to demonstrate concentrations of the drug required for effective use . ( iii ) A description of any known mechanisms of resistance to the drug , including results of any known epi- demiologic ...
... results of in vitro preclinical stud- ies to demonstrate concentrations of the drug required for effective use . ( iii ) A description of any known mechanisms of resistance to the drug , including results of any known epi- demiologic ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning